[go: up one dir, main page]

MA51074A - Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine - Google Patents

Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Info

Publication number
MA51074A
MA51074A MA051074A MA51074A MA51074A MA 51074 A MA51074 A MA 51074A MA 051074 A MA051074 A MA 051074A MA 51074 A MA51074 A MA 51074A MA 51074 A MA51074 A MA 51074A
Authority
MA
Morocco
Prior art keywords
compositions
methods
treating disorders
follistatin polypeptides
follistatin
Prior art date
Application number
MA051074A
Other languages
English (en)
Inventor
Asya Grinberg
Ravindra Kumar
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA51074A publication Critical patent/MA51074A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA051074A 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine MA51074A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04

Publications (1)

Publication Number Publication Date
MA51074A true MA51074A (fr) 2020-10-14

Family

ID=54767384

Family Applications (2)

Application Number Title Priority Date Filing Date
MA051075A MA51075A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
MA051074A MA51074A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA051075A MA51075A (fr) 2014-06-04 2015-06-04 Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine

Country Status (12)

Country Link
US (2) US10023621B2 (fr)
EP (2) EP3152237B1 (fr)
JP (3) JP6568110B2 (fr)
KR (4) KR102132144B1 (fr)
CN (2) CN113583104A (fr)
AU (2) AU2015269333B2 (fr)
BR (1) BR112016028520A2 (fr)
CA (1) CA2950754C (fr)
EA (2) EA202090632A1 (fr)
MA (2) MA51075A (fr)
MX (2) MX2016015868A (fr)
WO (1) WO2015187977A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612041B2 (en) 2005-11-23 2009-11-03 Acceleron Pharma Inc. Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth
EP2315602A4 (fr) 2008-06-26 2011-11-02 Acceleron Pharma Inc Procédés pour administrer un antagoniste d' actriib et surveiller des patients traités
CN104902915B (zh) 2013-01-25 2018-07-06 夏尔人类遗传性治疗公司 治疗杜兴氏肌营养不良的卵泡抑素
BR112016028520A2 (pt) 2014-06-04 2017-10-24 Acceleron Pharma Inc métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
KR20170129233A (ko) 2015-03-26 2017-11-24 악셀레론 파마 인코포레이티드 폴리스타틴-관련된 융합 단백질 및 이들의 용도
AU2017228475A1 (en) * 2016-03-04 2018-09-13 Shire Human Genetic Therapies, Inc. Recombinant follistatin-Fc fusion proteins and use in treating duchenne muscular dystrophy
WO2018176065A1 (fr) * 2017-03-23 2018-09-27 Oregon State University Compositions et méthodes destinées au traitement des maladies associées à l'atrophie musculaire
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (fr) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute Procédé thérapeutique pour augmenter la masse musculaire chez un sujet
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
CN111936617A (zh) * 2018-03-16 2020-11-13 益缪索夫特公司 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法
EP3769779B1 (fr) * 2018-03-21 2023-12-27 Soulyoung Biotech Co., Ltd Composition visant à favoriser la croissance musculaire locale ou à ralentir ou prévenir l'atrophie musculaire locale et son utilisation
WO2019191204A1 (fr) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Polypeptides de follistatine pour le traitement de la contracture musculaire
CN112673019A (zh) * 2018-05-17 2021-04-16 豪斯制药研究实验室有限责任公司 卵泡抑素的抑制
US12246042B2 (en) 2018-08-29 2025-03-11 Myos Corp. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
KR20250024825A (ko) 2022-06-15 2025-02-19 유씨비 바이오파마 에스알엘 폴리스타틴-fc 융합 단백질
KR20250036807A (ko) 2022-06-15 2025-03-14 유씨비 바이오파마 에스알엘 신장 질환의 예방, 치료 또는 완화를 위한 융합 단백질
WO2024121351A1 (fr) * 2022-12-07 2024-06-13 Lodberg Andreas Composés de liaison à une matrice extracellulaire pour le chargement localisé d'agents thérapeutiques ou diagnostiques

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (fr) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Procede pour ameliorer la stabilite des glycoproteines
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
WO1992013947A1 (fr) 1991-02-08 1992-08-20 Progenics Pharmaceuticals, Inc. CHIMERES DE CD4-GAMMA2 ET DE CD4-IgG2
EP0661993B1 (fr) 1992-09-16 1997-05-07 Genentech, Inc. Protection contre des lesions hepatiques au moyen du facteur de croissance d'hepatocytes (hgf)
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999006559A1 (fr) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Procedes d'identification des recepteurs des facteurs de differenciation de la croissance
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
WO2001009368A1 (fr) 1999-07-30 2001-02-08 The General Hospital Corporation Antagonistes de la follistatine
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
WO2003072715A2 (fr) 2002-02-21 2003-09-04 Wyeth Proteine contenant un domaine de follistatine
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
WO2004082710A1 (fr) 2003-03-21 2004-09-30 Lorantis Limited Traitement de maladies allergiques utilisant un modulateur de la voie de signalisation notch
MXPA05012965A (es) 2003-06-02 2006-03-09 Wyeth Corp Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello.
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
WO2005033134A2 (fr) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Therapeutique et utilisations d'une proteine secretee
WO2005032578A1 (fr) 2003-10-06 2005-04-14 Monash University Methode de traitement
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2006012627A2 (fr) * 2004-07-23 2006-02-02 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
PT1915397E (pt) 2005-08-19 2015-04-30 Univ Pennsylvania Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
AU2006321906C1 (en) 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
WO2008030367A2 (fr) 2006-09-01 2008-03-13 The General Hospital Corporation Inhibiteurs sélectifs de la myostatine
CA2693178C (fr) 2006-11-29 2018-12-04 Nationwide Children's Hospital, Inc. Inhibition de la myostatine destinee a ameliorer le muscle et/ou a ameliorer la fonction musculaire
PL2124999T3 (pl) 2006-12-18 2013-03-29 Acceleron Pharma Inc Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2315602A4 (fr) * 2008-06-26 2011-11-02 Acceleron Pharma Inc Procédés pour administrer un antagoniste d' actriib et surveiller des patients traités
DK2318028T3 (da) * 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
MX340451B (es) * 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
WO2012025536A1 (fr) * 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Anticorps contre il-18r1 et leurs utilisations
KR101973930B1 (ko) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
EP2847329A4 (fr) * 2012-04-02 2016-08-10 Moderna Therapeutics Inc Polynucléotides modifiés pour la production de protéines cytoplasmiques et cytosquelettiques
ES2663993T3 (es) 2012-05-17 2018-04-17 Paranta Biosciences Limited Uso de folistatina o de un inhibidor de activina para prevenir o tratar la disfunción del injerto de tejido
EP2866826A1 (fr) * 2012-06-27 2015-05-06 Arthrogen BV Combinaison de traitement d'un trouble inflammatoire
CN104902915B (zh) 2013-01-25 2018-07-06 夏尔人类遗传性治疗公司 治疗杜兴氏肌营养不良的卵泡抑素
WO2014187807A1 (fr) * 2013-05-21 2014-11-27 Arcarios B.V. Dérivés de follistatine
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
BR112016028520A2 (pt) 2014-06-04 2017-10-24 Acceleron Pharma Inc métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina
KR20170129233A (ko) 2015-03-26 2017-11-24 악셀레론 파마 인코포레이티드 폴리스타틴-관련된 융합 단백질 및 이들의 용도
JP2020519291A (ja) 2017-05-12 2020-07-02 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用

Also Published As

Publication number Publication date
AU2020210315A1 (en) 2020-08-27
EP3152237B1 (fr) 2020-04-01
KR102077286B1 (ko) 2020-02-13
AU2015269333A1 (en) 2016-12-15
MA51075A (fr) 2020-10-14
US20160185836A1 (en) 2016-06-30
KR102305109B1 (ko) 2021-09-27
KR20170005891A (ko) 2017-01-16
CA2950754A1 (fr) 2015-12-10
US10023621B2 (en) 2018-07-17
EP3152237A4 (fr) 2017-11-01
CN106795224A (zh) 2017-05-31
EA202090632A1 (ru) 2020-07-31
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
JP2017518303A (ja) 2017-07-06
MX2021006017A (es) 2021-07-06
EA201692529A1 (ru) 2017-05-31
BR112016028520A2 (pt) 2017-10-24
KR20210119546A (ko) 2021-10-05
US10954279B2 (en) 2021-03-23
WO2015187977A1 (fr) 2015-12-10
MX2016015868A (es) 2017-04-05
AU2015269333B2 (en) 2020-05-07
EP3721892A1 (fr) 2020-10-14
JP2021095416A (ja) 2021-06-24
EP3721892B1 (fr) 2024-05-22
CN113583104A (zh) 2021-11-02
EP3152237A1 (fr) 2017-04-12
JP6568110B2 (ja) 2019-08-28
CA2950754C (fr) 2021-10-26
JP6856716B2 (ja) 2021-04-07
JP2019203017A (ja) 2019-11-28
CN106795224B (zh) 2021-05-18
KR20200084064A (ko) 2020-07-09
EA035455B1 (ru) 2020-06-18
KR102132144B1 (ko) 2020-07-09

Similar Documents

Publication Publication Date Title
MA51075A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
IL291533A (en) Compounds and preparations including them for the treatment of diseases of the central nervous system
FR25C1001I1 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3364993A4 (fr) Procédés pour traiter le syndrome d'angelman et des troubles associés
SMT202000414T1 (it) Composizioni e metodi per trattare disturbi del snc
SI3224269T1 (sl) Sestavki in metode za zdravljenje CNS motenj
PT3250210T (pt) Composições e métodos para o tratamento de distúrbios do snc
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA44886A (fr) Compositions et méthode pour traiter des troubles acide-base
EP3180022A4 (fr) Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
EP3703706A4 (fr) Compositions et méthode pour traiter des troubles acide-base
EP3291693A4 (fr) Régime alimentaire imitant et favorisant le jeûne pour le traitement de l'hypertension et des troubles lipidiques
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3358929A4 (fr) Procédés et appareils pour le traitement d'une matière agricole
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3204028A4 (fr) Composition synergique pour l'arthrose
EP3551162C0 (fr) Composition appropriée pour le nettoyage
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
MA44747A (fr) Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
EP3377073A4 (fr) Méthodes et compositions pour traiter des troubles et des maladies à l'aide de la protéine de survie des motoneurones (smn)
EP3294339A4 (fr) Méthodes et compositions pour le traitement de l'arthrite
EP3328428A4 (fr) Procédés et compositions pour le traitement de maladies et de troubles immunomodulateurs
FR3040122B1 (fr) Casier formant nasse pour des mollusques
EP3436021A4 (fr) Compositions et méthodes pour traiter des troubles du déficit de l'attention